140 related articles for article (PubMed ID: 37607867)
1. Chemical Probes for Profiling of MALT1 Protease Activity.
Verhelst SHL; Prothiwa M
Chembiochem; 2023 Nov; 24(21):e202300444. PubMed ID: 37607867
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
Ferch U; Kloo B; Gewies A; Pfänder V; Düwel M; Peschel C; Krappmann D; Ruland J
J Exp Med; 2009 Oct; 206(11):2313-20. PubMed ID: 19841089
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis.
Mc Guire C; Elton L; Wieghofer P; Staal J; Voet S; Demeyer A; Nagel D; Krappmann D; Prinz M; Beyaert R; van Loo G
J Neuroinflammation; 2014 Jul; 11():124. PubMed ID: 25043939
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of MALT1 protease activity suppresses endothelial activation via enhancing MCPIP1 expression.
Li Y; Huang S; Huang X; Li X; Falcon A; Soutar A; Bornancin F; Jiang Z; Xin HB; Fu M
Cell Signal; 2018 Oct; 50():1-8. PubMed ID: 29913212
[TBL] [Abstract][Full Text] [Related]
5. Function and targeting of MALT1 paracaspase in cancer.
O'Neill TJ; Tofaute MJ; Krappmann D
Cancer Treat Rev; 2023 Jun; 117():102568. PubMed ID: 37126937
[TBL] [Abstract][Full Text] [Related]
6. The protease activity of the paracaspase MALT1 is controlled by monoubiquitination.
Pelzer C; Cabalzar K; Wolf A; Gonzalez M; Lenz G; Thome M
Nat Immunol; 2013 Apr; 14(4):337-45. PubMed ID: 23416615
[TBL] [Abstract][Full Text] [Related]
7. Probes to monitor activity of the paracaspase MALT1.
Hachmann J; Edgington-Mitchell LE; Poreba M; Sanman LE; Drag M; Bogyo M; Salvesen GS
Chem Biol; 2015 Jan; 22(1):139-47. PubMed ID: 25556944
[TBL] [Abstract][Full Text] [Related]
8. A patent review of MALT1 inhibitors (2013-present).
Hamp I; O'Neill TJ; Plettenburg O; Krappmann D
Expert Opin Ther Pat; 2021 Dec; 31(12):1079-1096. PubMed ID: 34214002
[TBL] [Abstract][Full Text] [Related]
9. MALT1 protease: a new therapeutic target in B lymphoma and beyond?
McAllister-Lucas LM; Baens M; Lucas PC
Clin Cancer Res; 2011 Nov; 17(21):6623-31. PubMed ID: 21868762
[TBL] [Abstract][Full Text] [Related]
10. Detection of recombinant and cellular MALT1 paracaspase activity.
Nagel D; Krappmann D
Methods Mol Biol; 2015; 1280():239-46. PubMed ID: 25736752
[TBL] [Abstract][Full Text] [Related]
11. The Paracaspase MALT1.
Hachmann J; Salvesen GS
Biochimie; 2016 Mar; 122():324-38. PubMed ID: 26386283
[TBL] [Abstract][Full Text] [Related]
12. MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies.
Liang X; Cao Y; Li C; Yu H; Yang C; Liu H
Med Res Rev; 2021 Jul; 41(4):2388-2422. PubMed ID: 33763890
[TBL] [Abstract][Full Text] [Related]
13. MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas.
Minderman M; Lantermans HC; Grüneberg LJ; Cillessen SAGM; Bende RJ; van Noesel CJM; Kersten MJ; Pals ST; Spaargaren M
Blood Cancer J; 2023 Mar; 13(1):37. PubMed ID: 36922488
[TBL] [Abstract][Full Text] [Related]
14. Normal lymphocyte homeostasis and function in MALT1 protease-resistant HOIL-1 knock-in mice.
Skordos I; Driege Y; Haegman M; Kreike M; Staal J; Demeyer A; Beyaert R
FEBS J; 2023 Apr; 290(8):2032-2048. PubMed ID: 36479846
[TBL] [Abstract][Full Text] [Related]
15. MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression.
Afonina IS; Elton L; Carpentier I; Beyaert R
FEBS J; 2015 Sep; 282(17):3286-97. PubMed ID: 25996250
[TBL] [Abstract][Full Text] [Related]
16. Ancient Origin of the CARD-Coiled Coil/Bcl10/MALT1-Like Paracaspase Signaling Complex Indicates Unknown Critical Functions.
Staal J; Driege Y; Haegman M; Borghi A; Hulpiau P; Lievens L; Gul IS; Sundararaman S; Gonçalves A; Dhondt I; Pinzón JH; Braeckman BP; Technau U; Saeys Y; van Roy F; Beyaert R
Front Immunol; 2018; 9():1136. PubMed ID: 29881386
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
18. Targeting MALT1 Proteolytic Activity in Immunity, Inflammation and Disease: Good or Bad?
Demeyer A; Staal J; Beyaert R
Trends Mol Med; 2016 Feb; 22(2):135-150. PubMed ID: 26787500
[TBL] [Abstract][Full Text] [Related]
19. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
Seshadri MR; Melnick AM
Leuk Lymphoma; 2022 Apr; 63(4):789-798. PubMed ID: 34783281
[TBL] [Abstract][Full Text] [Related]
20. The T-cell fingerprint of MALT1 paracaspase revealed by selective inhibition.
Bardet M; Unterreiner A; Malinverni C; Lafossas F; Vedrine C; Boesch D; Kolb Y; Kaiser D; Glück A; Schneider MA; Katopodis A; Renatus M; Simic O; Schlapbach A; Quancard J; Régnier CH; Bold G; Pissot-Soldermann C; Carballido JM; Kovarik J; Calzascia T; Bornancin F
Immunol Cell Biol; 2018 Jan; 96(1):81-99. PubMed ID: 29359407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
